Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA's Pending HAP/VAP Guidance Could Further Dampen Antibiotic Drug Development

Oct 11 2010

• By Shirley Haley

Related Content

Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus

Jun 28 2010

Biotech's Role In Rebuilding Big Pharma's Neglected Antibiotic Pipeline

Sep 27 2010

FDA's New Skin Infection Endpoint Needs Refinement, Advisory Panel Says

Sep 13 2010

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

Sep 06 2010

Theravance Could Face Prospect Of Another Trial For Vibativ In HAP

Feb 01 2010

Antibiotic Development Incentive Menu: Options Getting Longer

Jul 01 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window